Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469054 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HTTCYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL678936 | 1.00 | ALDH1A1 (0.38) | ALDH1A1HTTCYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL7094238 | 0.76 | PRKCA (0.40) | — | |
| SCHEMBL679076 | 0.74 | ALDH1A1 (0.39) | ALDH1A1HTTCYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL679077 | 0.74 | ALDH1A1 (0.39) | ALDH1A1HTTCYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL12815113 | 0.70 | ALDH1A1 (0.41) | ALDH1A1HTTCYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL21709500 | 0.66 | ALDH1A1 (0.43) | ALDH1A1HTTCYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL31229329 | 0.66 | TSHR (0.50) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL2558460 | 0.63 | — | — | |
| SCHEMBL746873 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365969-B1 | Novel anti-biofilm agents | YISSUM RES DEV CO (IL) | 2017-03-22 | — | — | EP | disclosed |
| US-8865909-B2 | Anti-biofilm agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-21 | — | — | US | disclosed |
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2011-11-17 | — | — | US | disclosed |
| EP-2365969-A1 | Novel anti-biofilm agents | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010058402-A1 | NOVEL ANTI-BIOFILM AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | PYCARD, DNM2, MMP8 | ALDH1A1 1605/4885HTT 3403/4885CYP3A4 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.